Dalcetrapib JTT-705 211513-37-0
Dalcetrapib or JTT-705 is a CETP inhibitor in development by Hoffmann–La Roche. A 24 week clinical trial showed increased HDL levels. five phase II trials had started and there was no evidence of the raised blood pressure seen with torcetrapib. dal-VESSEL phase IIb trial found no evidence of flow-mediated dilatation improvement. dal-OUTCOMES phase III trial passed its first interim review in July on 2011 and will continue as planned.
read more [+]| Systematic (IUPAC) name: | S-[2-({[1-(2-ethylbutyl)cyclohexyl]carbonyl}amino)phenyl] 2-methylpropanethioate |
|---|---|
| Dalcetrapib JTT-705 CAS number: | 211513-37-0 |
| ATC code: | |
| PubChem: | 6918540 |
| DrugBank: | |
| Formula: | C23H35NO2S |
| Molecular mass: | 389.5945 g/mol |
| Dalcetrapib JTT-705 Assay/Purity: | Typically NLT 98% |
